Charles River Laboratories Other Operating Income or Expenses 2010-2025 | CRL
Charles River Laboratories annual/quarterly other operating income or expenses history and growth rate from 2010 to 2025. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
- Charles River Laboratories other operating income or expenses for the quarter ending March 31, 2025 were $0M, a 0% increase year-over-year.
- Charles River Laboratories other operating income or expenses for the twelve months ending March 31, 2025 were $0M, a 0% increase year-over-year.
- Charles River Laboratories annual other operating income or expenses for 2024 were $0B, a 0% decline from 2023.
- Charles River Laboratories annual other operating income or expenses for 2023 were $0B, a 0% decline from 2022.
- Charles River Laboratories annual other operating income or expenses for 2022 were $0B, a 0% decline from 2021.
| Charles River Laboratories Annual Other Operating Income or Expenses (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| 2020 | $0 |
| 2019 | $0 |
| 2018 | $0 |
| 2017 | $0 |
| 2016 | $0 |
| 2015 | $0 |
| 2014 | $0 |
| 2013 | $0 |
| 2012 | $0 |
| 2011 | $-7 |
| 2010 | $-121 |
| 2009 | $0 |
| Charles River Laboratories Quarterly Other Operating Income or Expenses (Millions of US $) |
|
|---|---|
| 2025-03-31 | |
| 2024-12-31 | |
| 2024-09-30 | |
| 2024-06-30 | |
| 2024-03-31 | |
| 2023-12-31 | |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| 2020-03-31 | |
| 2019-12-31 | |
| 2019-09-30 | |
| 2019-06-30 | |
| 2019-03-31 | |
| 2018-12-31 | |
| 2018-09-30 | |
| 2018-06-30 | |
| 2018-03-31 | |
| 2017-12-31 | |
| 2017-09-30 | |
| 2017-06-30 | |
| 2017-03-31 | |
| 2016-12-31 | |
| 2016-09-30 | |
| 2016-06-30 | |
| 2016-03-31 | |
| 2015-12-31 | |
| 2015-09-30 | |
| 2015-06-30 | |
| 2015-03-31 | |
| 2014-12-31 | |
| 2014-09-30 | |
| 2014-06-30 | |
| 2014-03-31 | |
| 2013-12-31 | |
| 2013-09-30 | |
| 2013-06-30 | |
| 2013-03-31 | |
| 2012-12-31 | |
| 2012-09-30 | |
| 2012-06-30 | |
| 2012-03-31 | |
| 2011-12-31 | |
| 2011-09-30 | |
| 2011-06-30 | |
| 2011-03-31 | |
| 2010-12-31 | $-91 |
| 2010-09-30 | $-30 |
| 2010-06-30 | |
| 2010-03-31 | |
| 2009-12-31 | |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $8.765B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $148.115B | 27.47 |
| CVS Health (CVS) | United States | $75.901B | 9.43 |
| Elevance Health (ELV) | United States | $65.016B | 8.74 |
| Cencora (COR) | United States | $56.164B | 19.54 |
| DiDi Global (DIDIY) | China | $25.650B | 27.25 |
| Labcorp Holdings (LH) | United States | $21.906B | 17.29 |
| Natera (NTRA) | United States | $18.548B | 0.00 |
| BioMerieux (BMXMF) | France | $17.068B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $15.156B | 0.00 |
| ICON (ICLR) | Ireland | $14.957B | 14.39 |
| CochLear (CHEOY) | Australia | $13.609B | 0.00 |
| Solventum (SOLV) | United States | $12.725B | 13.47 |
| Medpace Holdings (MEDP) | United States | $12.583B | 33.30 |
| Revvity (RVTY) | United States | $11.135B | 19.32 |
| Viatris (VTRS) | United States | $10.786B | 3.71 |
| Avantor (AVTR) | United States | $9.547B | 13.87 |
| Sonic Healthcare (SKHHY) | Australia | $9.074B | 0.00 |
| HealthEquity (HQY) | United States | $8.282B | 36.28 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.001B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $5.183B | 30.52 |
| Amplifon S.p.A (AMFPF) | Italy | $5.058B | 27.69 |
| BrightSpring Health Services (BTSG) | United States | $3.534B | 32.42 |
| Sotera Health (SHC) | United States | $3.446B | 19.58 |
| Surgery Partners (SGRY) | United States | $2.862B | 37.22 |
| Organon (OGN) | United States | $2.636B | 2.80 |
| GeneDx Holdings (WGS) | United States | $2.619B | 60.38 |
| Concentras Parent (CON) | United States | $2.589B | 14.96 |
| Alignment Healthcare (ALHC) | United States | $2.331B | 0.00 |
| Progyny (PGNY) | United States | $1.957B | 43.08 |
| PACS (PACS) | United States | $1.757B | 0.00 |
| Premier (PINC) | United States | $1.749B | 13.27 |
| GoodRx Holdings (GDRX) | United States | $1.739B | 34.79 |
| Ardent Health (ARDT) | United States | $1.532B | 6.53 |
| Teladoc Health (TDOC) | United States | $1.321B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.192B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.088B | 8.28 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.875B | 300.00 |
| Agilon Health (AGL) | United States | $0.799B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.740B | 6.93 |
| CareDx (CDNA) | United States | $0.708B | 11.06 |
| Embecta (EMBC) | United States | $0.628B | 4.23 |
| So-Young (SY) | China | $0.507B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.489B | 0.00 |
| Nutex Health (NUTX) | United States | $0.474B | 7.18 |
| Sonida Senior Living (SNDA) | United States | $0.469B | 0.00 |
| Omada Health (OMDA) | $0.468B | 0.00 | |
| LifeMD (LFMD) | United States | $0.464B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.456B | 10.27 |
| SBC Medicals (SBC) | United States | $0.454B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.401B | 0.00 |
| Enhabit (EHAB) | United States | $0.337B | 27.75 |
| Oncology Institute (TOI) | United States | $0.323B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.276B | 0.00 |
| Beauty Health (SKIN) | United States | $0.213B | 0.00 |
| DocGo (DCGO) | United States | $0.145B | 23.67 |
| Sera Prognostics (SERA) | United States | $0.109B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.086B | 0.00 |
| KindlyMD (NAKA) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.061B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Biodesix (BDSX) | United States | $0.057B | 0.00 |
| ModivCare (MODV) | United States | $0.043B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.042B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.040B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.018B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.011B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.011B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |